Deep brain stimulation (DBS) is an effective treatment and has provided unique insights into
the dynamic circuit architecture of brain disorders. This Review illustrates our current …

Deep brain stimulation (DBS) of 3 different targets is the most important therapeutic
innovation of the past 30 years for patients with fluctuating Parkinson's disease (PD) …

Exaggerated basal ganglia beta activity (13–35 Hz) is commonly found in patients with
Parkinson's disease and can be suppressed by dopaminergic medication, with the degree of …

Advancing conventional open‐loop DBS as a therapy for PD is crucial for overcoming
important issues such as the delicate balance between beneficial and adverse effects and …

Background Millions of patients around the world are affected by neurological and
psychiatric disorders. Deep brain stimulation (DBS) is a device-based therapy that could …

Advanced Parkinson's disease is characterized by the presence of motor fluctuations,
various degree of dyskinesia, and disability with functional impact on activities of daily living …

Deep brain stimulation (DBS) represents one of the major clinical breakthroughs in the age
of translational neuroscience. In 1987, Benabid and colleagues demonstrated that high …

Pathologically increased beta power has been described as a biomarker for Parkinson's
disease (PD) and related to prolonged bursts of subthalamic beta synchronization. Here, we …

Bradykinesia is reported to correlate with subthalamic beta power (13–35 Hz) recorded at
rest in Parkinson's disease (PD). Pilot studies suggest adaptive deep brain stimulation …

This review is part of the series on the clinical neurophysiology of movement disorders. It
focuses on Parkinson's disease and parkinsonism. The topics covered include the …